Sven Borchmann

1.6k total citations
46 papers, 612 citations indexed

About

Sven Borchmann is a scholar working on Pathology and Forensic Medicine, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sven Borchmann has authored 46 papers receiving a total of 612 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pathology and Forensic Medicine, 22 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sven Borchmann's work include Lymphoma Diagnosis and Treatment (31 papers), Lung Cancer Treatments and Mutations (9 papers) and Cancer Genomics and Diagnostics (8 papers). Sven Borchmann is often cited by papers focused on Lymphoma Diagnosis and Treatment (31 papers), Lung Cancer Treatments and Mutations (9 papers) and Cancer Genomics and Diagnostics (8 papers). Sven Borchmann collaborates with scholars based in Germany, United States and Netherlands. Sven Borchmann's co-authors include Andreas Engert, Peter Borchmann, Bastian von Tresckow, Michael Fuchs, Stephanie Sasse, Horst Müller, Paul J. Bröckelmann, Helen Goergen, Alexander Craig and David M. Kurtz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Oncogene.

In The Last Decade

Sven Borchmann

40 papers receiving 608 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sven Borchmann Germany 15 375 298 117 110 109 46 612
Jia-Jia Huang China 15 303 0.8× 324 1.1× 120 1.0× 60 0.5× 71 0.7× 25 575
Filiz Şen United States 16 278 0.7× 213 0.7× 124 1.1× 55 0.5× 63 0.6× 42 623
Joo-Seop Chung South Korea 14 310 0.8× 211 0.7× 200 1.7× 106 1.0× 110 1.0× 46 690
Akihiro Ohmoto Japan 14 114 0.3× 418 1.4× 62 0.5× 99 0.9× 52 0.5× 75 706
Farid Kosari Iran 10 241 0.6× 172 0.6× 44 0.4× 40 0.4× 70 0.6× 41 474
Claudia Corrado Argentina 14 336 0.9× 265 0.9× 35 0.3× 109 1.0× 126 1.2× 28 661
Arushi Khurana United States 13 182 0.5× 250 0.8× 34 0.3× 38 0.3× 82 0.8× 79 491
Sally Baron‐Hay Australia 14 122 0.3× 388 1.3× 63 0.5× 70 0.6× 37 0.3× 48 775
Hang Yang China 13 156 0.4× 309 1.0× 80 0.7× 89 0.8× 36 0.3× 51 624
Mehmet Akce United States 16 193 0.5× 847 2.8× 184 1.6× 255 2.3× 58 0.5× 115 1.2k

Countries citing papers authored by Sven Borchmann

Since Specialization
Citations

This map shows the geographic impact of Sven Borchmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sven Borchmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sven Borchmann more than expected).

Fields of papers citing papers by Sven Borchmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sven Borchmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sven Borchmann. The network helps show where Sven Borchmann may publish in the future.

Co-authorship network of co-authors of Sven Borchmann

This figure shows the co-authorship network connecting the top 25 collaborators of Sven Borchmann. A scholar is included among the top collaborators of Sven Borchmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sven Borchmann. Sven Borchmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Xin, Sven Borchmann, Zhenguo Cheng, et al.. (2025). Bispecific Nanosystems Enable Multieffector Immune Cell Retargeting for Hematologic Malignancy Therapy. Advanced Science. 12(39). e09103–e09103.
2.
Mariette, Xavier, Sven Borchmann, Sandrine Aspeslagh, et al.. (2025). Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open. 11(1). e005033–e005033. 1 indexed citations
3.
Heger, Jan‐Michel, Jonathan M. Weiss, Christian Becker, et al.. (2024). Noninvasive minimal residual disease assessment in relapsed/refractory large B‐cell lymphoma using digital droplet PCR. European Journal Of Haematology. 112(6). 957–963. 5 indexed citations
4.
Wagner, Dorothea, Sven Borchmann, Alex A. Adjei, et al.. (2024). Sex differences in the pharmacokinetics of anticancer drugs: a systematic review. ESMO Open. 9(12). 104002–104002. 9 indexed citations
5.
6.
Özdemir, Berna C., Anke Richters, Sabine Oertelt‐Prigione, et al.. (2024). 1592P Awareness and interest of oncology professionals in sex and gender differences in cancer risk and outcome: Analysis of an ESMO Gender Medicine Task Force survey. Annals of Oncology. 35. S959–S959.
7.
Mariette, Xavier, Sven Borchmann, Sandrine Aspeslagh, et al.. (2023). POS0824 CARDIOVASCULAR (CV) AND MALIGNANCY EVENTS IN THE FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) CLINICAL DEVELOPMENT PROGRAM UP TO 8.3 YEARS. Annals of the Rheumatic Diseases. 82. 707–708. 2 indexed citations
8.
Heger, Jan‐Michel, et al.. (2023). Clinical applications of circulating tumor DNA in Hodgkin lymphoma. Seminars in Hematology. 60(3). 157–163. 1 indexed citations
9.
Borchmann, Sven. (2021). An atlas of the tissue and blood metagenome in cancer reveals novel links between bacteria, viruses and cancer. Microbiome. 9(1). 94–94. 8 indexed citations
10.
García-Márquez, María A., Martin Thelen, Sarah Reinke, et al.. (2021). Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma. Leukemia. 36(3). 760–771. 19 indexed citations
11.
Craig, Alexander, et al.. (2020). Liquid biopsy in lymphoma: Molecular methods and clinical applications. Cancer Treatment Reviews. 91. 102106–102106. 50 indexed citations
12.
Borchmann, Sven, et al.. (2020). An update on disease biomarkers for Hodgkin lymphoma. Expert Review of Hematology. 13(5). 481–488. 4 indexed citations
13.
Borchmann, Sven, Erel Joffe, Craig H. Moskowitz, et al.. (2019). Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 133(20). 2121–2129. 26 indexed citations
14.
15.
Borchmann, Sven, Horst Müller, Heinz Haverkamp, et al.. (2018). Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG). Leukemia. 33(2). 439–446. 12 indexed citations
16.
Meder, Lydia, Mirjam Koker, Sven Borchmann, et al.. (2018). Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene. 37(42). 5682–5693. 31 indexed citations
17.
Borchmann, Sven, Horst Müller, & Andreas Engert. (2017). Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude. Scientific Reports. 7(1). 14903–14903. 11 indexed citations
18.
Borchmann, Sven, Bastian von Tresckow, & Andreas Engert. (2016). Current developments in the treatment of early-stage classical Hodgkin lymphoma. Current Opinion in Oncology. 28(5). 377–383. 16 indexed citations
19.
Böll, Boris, Helen Goergen, Karolin Behringer, et al.. (2016). Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 127(18). 2189–2192. 65 indexed citations
20.
Jachimowicz, Ron D., Sven Borchmann, & Achim Rothe. (2014). Multi-Specific Antibodies for Cancer Immunotherapy. BioDrugs. 28(4). 331–343. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jia-Jia Huang Breakdown of academic impact, for papers by Filiz Şen Breakdown of academic impact, for papers by Joo-Seop Chung Breakdown of academic impact, for papers by Akihiro Ohmoto Breakdown of academic impact, for papers by Farid Kosari Breakdown of academic impact, for papers by Claudia Corrado Breakdown of academic impact, for papers by Arushi Khurana Breakdown of academic impact, for papers by Sally Baron‐Hay Breakdown of academic impact, for papers by Hang Yang Breakdown of academic impact, for papers by Mehmet Akce
Rankless by CCL
2026